Michael F. Berger

89.6k total citations · 14 hit papers
325 papers, 17.3k citations indexed

About

Michael F. Berger is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael F. Berger has authored 325 papers receiving a total of 17.3k indexed citations (citations by other indexed papers that have themselves been cited), including 166 papers in Cancer Research, 130 papers in Oncology and 110 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael F. Berger's work include Cancer Genomics and Diagnostics (154 papers), Genetic factors in colorectal cancer (52 papers) and Lung Cancer Treatments and Mutations (51 papers). Michael F. Berger is often cited by papers focused on Cancer Genomics and Diagnostics (154 papers), Genetic factors in colorectal cancer (52 papers) and Lung Cancer Treatments and Mutations (51 papers). Michael F. Berger collaborates with scholars based in United States, Canada and Spain. Michael F. Berger's co-authors include David B. Solit, Marc Ladanyi, Ahmet Zehir, Nikolaus Schultz, Helen Won, David M. Hyman, Elaine R. Mardis, Maria E. Arcila, Sasinya N. Scott and José Baselga and has published in prestigious journals such as Science, The Lancet and Nucleic Acids Research.

In The Last Decade

Michael F. Berger

300 papers receiving 17.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers

2016 862 citations Nikolaus Schultz, Michael F. Berger et al. profile →
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

2013 855 citations Helen Won, Michael F. Berger et al. profile →
Diversity and Complexity in DNA Recognition by Transcription Factors

2009 761 citations Gwenaël Badis, Michael F. Berger et al. Science profile →
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

2017 738 citations David M. Hyman, Ahmet Zehir et al. Science profile →
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

2011 732 citations Nikhil Wagle, Michael F. Berger et al. Journal of Clinical Oncology profile →
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes

2017 521 citations Ahmet Zehir, David M. Hyman et al. profile →
Genome Sequencing Identifies a Basis for Everolimus Sensitivity

2012 480 citations Gopa Iyer, Aphrothiti J. Hanrahan et al. Science profile →
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

2015 423 citations Paul K. Paik, Alexander Drilon et al. Cancer Discovery profile →
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers

2018 374 citations Irina Ostrovnaya, Mark J. Bluth et al. Journal of Clinical Oncology profile →
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention

2018 369 citations Ryan Ptashkin, Emmet Jordan et al. Clinical Cancer Research profile →
The emerging clinical relevance of genomics in cancer medicine

2018 367 citations Michael F. Berger et al. profile →
Genome doubling shapes the evolution and prognosis of advanced cancers

2018 343 citations Ahmet Zehir, Walid K. Chatila et al. profile →
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets

2016 325 citations Natasha Rekhtman, M. Catherine Pietanza et al. Clinical Cancer Research profile →
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden

2019 289 citations Ryma Benayed, Michael Offin et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Michael F. Berger

Since Specialization

Citations

This map shows the geographic impact of Michael F. Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael F. Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael F. Berger more than expected).

Fields of papers citing papers by Michael F. Berger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael F. Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael F. Berger. The network helps show where Michael F. Berger may publish in the future.

Co-authorship network of co-authors of Michael F. Berger

This figure shows the co-authorship network connecting the top 25 collaborators of Michael F. Berger. A scholar is included among the top collaborators of Michael F. Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael F. Berger. Michael F. Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden breakdown → 2019 ·Clinical Cancer Research ·Ryma Benayed, Michael Offin, Kerry Mullaney, Purvil Sukhadia, Kelly Rios, Patrice Desmeules, Ryan Ptashkin, Helen Won, Jason C. Chang, Darragh Halpenny, Alison M. Schram, Charles M. Rudin, David M. Hyman, Maria E. Arcila, Michael F. Berger, Ahmet Zehir, Mark G. Kris, Alexander Drilon, Marc Ladanyi	289
2	Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer 2019 ·Clinical Cancer Research ·Elizabeth Won, (unknown), Walid K. Chatila, Jaclyn F. Hechtman, Joanne F. Chou, Geoffrey Y. Ku, Sree B. Chalasani, (unknown), (unknown), Avni M. Desai, Yaelle Tuvy, Michael F. Berger, Laura Tang, David P. Kelsen, Mark Schattner, David H. Ilson, Marinela Capanu, David B. Solit, Nikolaus Schultz, Yelena Y. Janjigian	14
3	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance 2018 ·Clinical Cancer Research ·Helena A. Yu, Ken Suzawa, Emmet Jordan, Ahmet Zehir, Ai Ni, Hyunjae R. Kim, Mark G. Kris, Matthew D. Hellmann, Bob T. Li, Romel Somwar, David B. Solit, Michael F. Berger, Maria E. Arcila, Gregory J. Riely, Marc Ladanyi	188
4	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition 2017 ·Cancer Research ·Rona Yaeger, Zhan Yao, David M. Hyman, Jaclyn F. Hechtman, Efsevia Vakiani, HuiYong Zhao, Wenjing Su, Lu Wang, Andrew Joelson, Andrea Cercek, José Baselga, Elisa de Stanchina, Leonard B. Saltz, Michael F. Berger, David B. Solit, Neal Rosen	60
5	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non–Small Cell Lung Cancer 2017 ·Clinical Cancer Research ·Kathryn C. Arbour, (unknown), Hyunjae R. Kim, Jordan Dienstag, Helena A. Yu, Francisco Sánchez-Vega, Piro Lito, Michael F. Berger, David B. Solit, Matthew D. Hellmann, Mark G. Kris, Charles M. Rudin, Ai Ni, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely	317
6	A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers 2017 ·Clinical Cancer Research ·Paul K. Paik, Ronglai Shen, Michael F. Berger, David Ferry, Jean‐Charles Soria, Alastair Mathewson, Claire Rooney, Neil R. Smith, Marie Cullberg, Elaine Kilgour, Dónal Landers, Paul Frewer, Nigel Brooks, Fabrice André	115
7	Osteosarcoma With Apparent Ewing Sarcoma Gene Rearrangement 2016 ·Journal of Pediatric Hematology/Oncology ·Melissa Mathias, Alexander J. Chou, Paul A. Meyers, Neerav Shukla, Meera Hameed, Narasimhan P. Agaram, Lu Wang, Michael F. Berger, Michael F. Walsh, Alex Kentsis	2
8	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets breakdown → 2016 ·Clinical Cancer Research ·Natasha Rekhtman, M. Catherine Pietanza, Matthew D. Hellmann, Jarushka Naidoo, Arshi Arora, Helen Won, Darragh Halpenny, Hangjun Wang, Shaozhou K. Tian, Anya M. Litvak, Paul K. Paik, Alexander Drilon, Nicholas D. Socci, John T. Poirier, Ronglai Shen, Michael F. Berger, André L. Moreira, William D. Travis, Charles M. Rudin, Marc Ladanyi	325
9	Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases 2015 ·Cancer Discovery ·Paul K. Paik, Ronglai Shen, Helen Won, Natasha Rekhtman, Lu Wang, Camelia S. Sima, Arshi Arora, Venkatraman Seshan, Marc Ladanyi, Michael F. Berger, Mark G. Kris	111
10	Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF -Mutant Metastatic Colorectal Cancer Patients 2015 ·Clinical Cancer Research ·Rona Yaeger, Andrea Cercek, Eileen M. O’Reilly, Diane Reidy‐Lagunes, Nancy E. Kemeny, (unknown), Marinela Capanu, Marc J. Gollub, Neal Rosen, Michael F. Berger, Mario E. Lacouture, Efsevia Vakiani, Leonard B. Saltz	221
11	Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping breakdown → 2015 ·Cancer Discovery ·Paul K. Paik, Alexander Drilon, Pang‐Dian Fan, Helena A. Yu, Natasha Rekhtman, Michelle S. Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F. Berger, Charles M. Rudin, Marc Ladanyi	423
12	Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies 2014 ·Cancer Discovery ·Omar Abdel‐Wahab, Virginia M. Klimek, (unknown), Agnès Viale, Donavan T. Cheng, Eun Hee Kim, Raajit K. Rampal, Mark J. Bluth, James J. Harding, Margaret K. Callahan, Taha Merghoub, Michael F. Berger, David B. Solit, Neal Rosen, Ross L. Levine, Paul B. Chapman	59
13	Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence 2014 ·Cancer Research ·Moriah H. Nissan, Christine A. Pratilas, Alexis M. Jones, Ricardo J. Ramirez, Helen Won, Cailian Liu, Shakuntala Tiwari, Li Ren Kong, Aphrothiti J. Hanrahan, Zhan Yao, Taha Merghoub, Antoni Ribas, Paul B. Chapman, Rona Yaeger, Barry S. Taylor, Nikolaus Schultz, Michael F. Berger, Neal Rosen, David B. Solit	219
14	Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy 2014 ·Clinical Cancer Research ·Martin H. Voss, A. Ari Hakimi, Can G. Pham, A. Rose Brannon, Ying‐Bei Chen, Luis F. Cunha, Oğuz Akın, Han Liu, Shugaku Takeda, Sasinya N. Scott, Nicholas D. Socci, Agnès Viale, Nikolaus Schultz, Chris Sander, Victor E. Reuter, Paul Russo, Emily H. Cheng, Robert J. Motzer, Michael F. Berger, James J. Hsieh	156
15	Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma 2013 ·Clinical Cancer Research ·Federica Catalanotti, David B. Solit, Melissa Pulitzer, Michael F. Berger, Sasinya N. Scott, Tunç Iyriboz, Mario E. Lacouture, Katherine S. Panageas, Jedd D. Wolchok, Richard D. Carvajal, Gary K. Schwartz, Neal Rosen, Paul B. Chapman	112
16	Genome Sequencing Identifies a Basis for Everolimus Sensitivity breakdown → 2012 ·Science ·Gopa Iyer, Aphrothiti J. Hanrahan, Matthew I. Milowsky, Hikmat Al‐Ahmadie, Sasinya N. Scott, Manickam Janakiraman, Mono Pirun, Chris Sander, Nicholas D. Socci, Irina Ostrovnaya, Agnès Viale, Adriana Heguy, (unknown), Timothy A. Chan, Bernard H. Bochner, Dean F. Bajorin, Michael F. Berger, Barry S. Taylor, David B. Solit	480
17	Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling breakdown → 2011 ·Journal of Clinical Oncology ·Nikhil Wagle, (unknown), Michael F. Berger, Matthew J. Davis, Allison M. Sawyer, Panisa Pochanard, Sarah M. Kehoe, Cory M. Johannessen, Laura E. MacConaill, William C. Hahn, Matthew Meyerson, Levi A. Garraway	732
18	High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing 2011 ·Cancer Discovery ·Nikhil Wagle, Michael F. Berger, Matthew J. Davis, Brendan Blumenstiel, Matthew DeFelice, Panisa Pochanard, Matthew D. Ducar, Paul Van Hummelen, Laura E. MacConaill, William C. Hahn, Matthew Meyerson, Stacey Gabriel, Levi A. Garraway	384
19	Diversity and Complexity in DNA Recognition by Transcription Factors breakdown → 2009 ·Science ·Gwenaël Badis, Michael F. Berger, Anthony Philippakis, Shaheynoor Talukder, Andrew R. Gehrke, Savina Jaeger, Esther T. Chan, Genita Metzler, Anastasia Vedenko, Xiaoyu Chen, Hanna S. Kuznetsov, (unknown), David Coburn, Daniel E. Newburger, Quaid Morris, Timothy R. Hughes, Martha L. Bulyk	761
20	Genome-Wide Promoter Analysis of the SOX4 Transcriptional Network in Prostate Cancer Cells 2009 ·Cancer Research ·Christopher D. Scharer, (unknown), Mohamed Ali‐Seyed, Michael F. Berger, Martha L. Bulyk, Carlos S. Moreno	163

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact